Mridula George, MD

Trials

Studies that name Mridula George, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:05 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07806630 · SHORTened Duration of TAMoxifen

  Rutgers, The State University of New Jersey · active not recruiting · High Risk for Invasive Breast Cancer · principal investigator
• Ph2
  NCT06568692 · A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  Processa Pharmaceuticals · terminated · Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer · principal investigator
• Ph2
  NCT05949021 · OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

  Mridula George, MD · active not recruiting · Triple Negative Breast Cancer (TNBC) · principal investigator
• Ph2
  NCT05559164 · Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

  Rutgers, The State University of New Jersey · recruiting · Cardiac Toxicity, Early-stage Breast Cancer · principal investigator
• Early Ph1
  NCT05333874 · CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

  Rutgers, The State University of New Jersey · active not recruiting · Breast Cancer, Early-Onset · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.